Get an estimate for your upcoming project
Biogeneric Excellence, Delivered.
Scaling the Future of Sustainable
Antibiotic Manufacturing.
ABOUT
Dalas Biotech
is a biotechnology and pharmaceutical firm committed to transforming antibiotic manufacturing by emphasising innovation and sustainability.
Scalable Manufacturing
Achieving revenue exceeding ₹1,000 crore, supported by substantial production capacity.
Global Reach
Exporters to 20+ Countries and expanding our presence in regulated markets.
Sustainability Focused
At the forefront of enzymatic, solvent-free production methods, significantly minimizing our environmental impact.
Amoxicillin
Production Capacity
6,000T+
annual capacity
Ampicillin
Production Capacity
1,200T+
annual capacity
Cloxacillin
Production Capacity
1,200T+
annual capacity
Cephalexin
Production Capacity
600T+
annual capacity
Cefadroxil
Production Capacity
600T+
annual capacity
Amoxicillin
Production Capacity
6,000T+
annual capacity
Ampicillin
Production Capacity
1,200T+
annual capacity
Cloxacillin
Production Capacity
1,200T+
annual capacity
Cephalexin
Production Capacity
600T+
annual capacity
Cefadroxil
Production Capacity
600T+
annual capacity
FACILITY
Dalas Biotech
operates a state-of-the-art, high-capacity manufacturing campus in Bhiwadi, Rajasthan, specializing in the production of bulk antibiotics, intermediates, and enzymes. Our facilities are meticulously designed to facilitate precision-driven and sustainable pharmaceutical manufacturing, ensuring we meet the increasing global demand effectively.
4
Manufacturing Units
Fully Integrated Production Process
State of the Art, Dedicated R&D Centre
OUR JOURNEY
25+ years and counting
worth of experience under our belt, Dalas Biotech is not just any player in the game – we're one of India’s leaders in enzymatic antibiotic manufacturing!
10,000T
Total Production
Capacity
+35%
Avg Growth per year in the last 10 Years.
20,000T
Delivered over the last
5 Years.
TRUSTED BY INDUSTRY LEADERS
SOCIAL RESPONSIBILITY
Dalas Biotech
believes responsible growth goes beyond manufacturing, embedding sustainability and social impact into everything we do. Our focus on eco-friendly processes, community support, and healthcare innovation ensures a healthier, more sustainable future. Through cleaner production, healthcare initiatives, and education support, we contribute to a more responsible pharmaceutical industry.
Amoxicillin
Class: Beta-lactam Antibiotic (Aminopenicillin)
Production Capacity
6,000T+
annual capacity
Click Here to
Inquire
Use Cases:
Effective for respiratory infections (pneumonia, bronchitis), skin infections, UTIs, and ear infections. Also a first-line treatment for strep throat, sinusitis, and middle ear infections.
Market Position & Demand:
It holds a strong market position as one of the most commonly prescribed antibiotics worldwide. Its broader bacterial coverage makes it a preferred choice over Penicillin.
Mechanism of Action:
The antibiotic works by inhibiting bacterial cell wall synthesis, weakening the bacterial structure and ultimately causing bacterial death.
Key Advantages:
Its key advantages include enhanced absorption, making it highly effective for oral treatments. It also boasts high stability and an extended shelf life, ensuring easier and broader global distribution.
Ampicillin
Class: Beta-lactam Antibiotic (Aminopenicillin)
Production Capacity
1,200T+
annual capacity
Click Here to
Inquire
Use Cases:
Treats bacterial meningitis, respiratory infections, UTIs, and endocarditis. Also used for preoperative infection prevention (surgical prophylaxis).
Market Position & Demand:
Widely used in hospitals and clinical settings, offering broad-spectrum coverage, often in combination with other antibiotics.
Mechanism of Action:
Inhibits peptidoglycan cross-linking, weakening bacterial cell walls and ultimately causing bacterial death.
Key Advantages:
Effective against Gram-positive bacteria and some Gram-negative bacteria, making it a versatile treatment option.
Cloxacillin
Class: Penicillinase-Resistant Beta-lactam Antibiotic
Production Capacity
2,400T+
annual capacity
Click Here to
Inquire
Use Cases:
Effectively treats staphylococcal infections, including skin infections, osteomyelitis, and septicemia. It is the preferred choice for bone and joint infections.
Market Position & Demand:
Resistant to penicillinase, making it highly effective against Staphylococcus aureus. Widely used in hospitals for managing serious infections.
Mechanism of Action:
Inhibits bacterial cell wall synthesis while remaining stable against beta-lactamase enzymes, ensuring effectiveness against resistant bacteria.
Key Advantages:
More effective against resistant Staphylococcus strains and well-absorbed in oral formulations, enhancing treatment success.
Cephalexin
Class: First-Generation Cephalosporin
Production Capacity
1,100T+
annual capacity
Click Here to
Inquire
Use Cases:
Effectively treats upper respiratory infections, skin infections, and bone infections. Also serves as an alternative to penicillins for patients with mild allergies.
Market Position & Demand:
A widely prescribed oral cephalosporin globally, especially favored for pediatric treatments due to its safety and effectiveness.
Mechanism of Action:
Inhibits bacterial cell wall synthesis, leading to bacterial lysis and eradication of the infection.
Key Advantages:
Provides broader coverage than penicillins, particularly against Gram-positive bacteria, and is generally well-tolerated with minimal side effects.
Cefadroxil
Class: First-Generation Cephalosporin
Production Capacity
1,000T+
annual capacity
Click Here to
Inquire
Use Cases:
Effectively treats tonsillitis, UTIs, and skin and soft tissue infections. Also used as an alternative for streptococcal and wound infections.
Market Position & Demand:
A widely used antibiotic for mild to moderate infections, often preferred as a safer alternative to penicillins.
Mechanism of Action:
Disrupts bacterial cell wall formation, leading to bacterial death and infection resolution.
Key Advantages:
Longer half-life allows for fewer daily doses, improving patient convenience. Effective against penicillin-resistant bacteria.